Diridavumab

Diridavumab is a monoclonal antibody designed for the treatment of Ebola virus disease. It was developed by Mapp Biopharmaceutical and is considered one of the most effective treatments for Ebola.

History[edit | edit source]

Diridavumab was first developed in response to the 2014-2016 Ebola virus epidemic in West Africa. It was fast-tracked for approval by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) due to the urgent need for an effective treatment for Ebola.

Mechanism of Action[edit | edit source]

As a monoclonal antibody, diridavumab works by binding to the Ebola virus and neutralizing it. This prevents the virus from entering host cells and replicating, thereby stopping the progression of the disease.

Clinical Trials[edit | edit source]

Several clinical trials have been conducted to test the safety and efficacy of diridavumab. These trials have shown that diridavumab is safe and effective in treating Ebola virus disease.

Side Effects[edit | edit source]

Like all medications, diridavumab can cause side effects. The most common side effects include fever, headache, and fatigue. However, these side effects are generally mild and go away on their own.

Availability[edit | edit source]

Diridavumab is currently available under an Emergency Use Authorization (EUA) from the FDA. This means that it can be used in emergency situations where there are no other available treatments.

See Also[edit | edit source]

Diridavumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.